ArticleInflammation2025
Alpha Ketoglutaric Acid attenuates LPS Induced Inflammatory Response by Inhibiting the PKCε/MAPK/P65 Signaling Pathway and Inhibit Oxidative Stress in Kupffer Cells.
Article in Inflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Alpha-Ketoglutarate: A Metabolic Regulator of Cellular Homeostasis and Pathophysiology.Biomedicines · 2026Review
- Integrative Network Pharmacology, Molecular Docking, and In Vitro Insights Into the Mechanism of Finger Citron for Non-Alcoholic Fatty Liver Disease.Food science & nutrition · 2026Article
- Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The inflammatory response is crucial in the progression of various liver diseases. Many diseases are linked with inflammation, such as ischemia and reperfusion injury, nonalcoholic steatohepatitis (NASH) and hepatic fibrosis. Research indicates that αKG attenuates NASH. However, the protective effect of αKG on KCs cell inflammation and its mechanism remain unclear. This study aimed to explore the role and mechanism of αKG in LPS-induced inflammation. The inflammatory damage model of KCs was induced by LPS. The study found that αKG supplementation significantly decreased inflammatory and antioxidant indexes in the LPS group, with a notable reduction in LPS-induced inflammation-related factors (P < 0.05). iNOS and COX2 are also used as indicators of macrophage inflammation, and αKG significantly alleviates LPS induced iNOS and COX2 levels (P < 0.05). Further detection of mitochondrial function and oxidative stress indexes showed that αKG supplementation significantly restored mitochondrial damage caused by LPS, inhibited ROS production, restored mitochondrial function, and improved cellular antioxidant capacity (P < 0.05). Finally, it was found that LPS treatment significantly promoted the activation of PKCε/MAPK/P65 signaling pathway, and αKG supplementation significantly inhibited the activation of signaling pathway and alleviated the pro-inflammatory effect of LPS (P < 0.05). The study demonstrated that αKG enhances the anti-inflammatory effects of KCs by decreasing ROS production and inhibiting the PKCε/MAPK/P65 signaling pathway. This is helpful for development the αKG related anti-inflammation drugs to relieving the liver inflammatory response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.